Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 8/20 | 0.71 |
| ▸ | KDR | P35968 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | UBE2N | P61088 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | RAD52 | P43351 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785974 | 0.95 | KDM4E (0.74) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL2975999 | 0.95 | KDM4E (0.74) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL6412162 | 0.86 | TEK (0.56) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL1787606 | 0.84 | SMN1; SMN2 (0.55) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL6201687 | 0.83 | ALDH1A1 (0.59) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL735560 | 0.81 | TNK2 (0.68) | KDM4EALDH1A1HPGDUBE2NSMN1; SMN2 | |
| SCHEMBL13271833 | 0.80 | KDM4E (0.76) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL14013982 | 0.80 | TEK (0.92) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL22320657 | 0.80 | TEK (0.47) | TEKKDRKDM4EALDH1A1HPGD | |
| SCHEMBL14020859 | 0.79 | KDM4E (0.74) | TEKKDRKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324222-B2 | Cyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | US | disclosed |
| EP-1966218-B1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AG (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2008131859-A2 | USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966218-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079861-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1425283-B1 | NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040259888-A1 | Novel 4-aminofuropyrimidines and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124665-A1 | Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, TK2, TPMT | TEK 199/4885KDR 511/4885KDM4E 4173/4885 |
| US-20040259888-A1 | Novel 4-aminofuropyrimidines and the use thereof | DPYD, TPMT, TYMP | TEK 950/4885KDR 3628/4885KDM4E 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.